Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective
Pharmaceutical Technology
MAY 24, 2023
This promise and growth are expected to continue as CGT, which have the potential to cover 70% of oncology drugs, are being developed to treat further disease types such as solid tumors. CGT drugs fall into two major categories: autologous and allogeneic. Differences in CGT vs traditional trials supply chain.
Let's personalize your content